PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PEPG	$2.54	-2.12%	460.57K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PEPG	$2.54	-2.1%	460.57K
3
4
5
6

PEPG

Get PepGen Inc. Data in Excel

Get PepGen Inc. Data in Excel